74 - References

References

82 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 References

1. Mallikaarjun S, et al. Pharmacokinetics, tolerability and safety of aripiprazole once-­monthly in adult schizophrenia: an open-­label, parallel-­arm, multiple-­dose study. SchizophrRes 2013; 150:281–288.
2. Correll CU, et al. Pharmacokinetic characteristics of long-­acting injectable antipsychotics for schizophrenia: an overview. CNS Drugs 2021; 35:39–59.
3. Wang Y, et al. Population pharmacokinetics and dosing simulations for aripiprazole 2-­month ready-­to-­use long-­acting injectable in adult patients with schizophrenia or bipolar I disorder. Clin Pharmacol Drug Dev 2024; 13:631–643.
4. Otsuka Pharmaceutical Co Ltd. Highlights of Prescribing Information. ABILIFY ASIMTUFII® (aripiprazole) extended-­release injectable suspension for intramuscular use. 2023 (last accessed November 2024); https://www.accessdata.fda.gov/drugsatfda_docs/label/ 2023/217006s000lbl.pdf.
5. Harlin M, et al. A randomized, open-­label, multiple-­dose, parallel-­arm, pivotal study to evaluate the safety, tolerability, and pharmacokinetics of aripiprazole 2-­month long-­acting injectable in adults with schizophrenia or bipolar I disorder. CNS Drugs 2023; 37:337–350.
6. Baune BT. Aripiprazole 2-­month ready-­to-­use 960 mg (Ari 2MRTU): review of its possible role in schizophrenia therapy. Curr Med Res Opin 2024; 40:87–96.
7. Alkermes Inc. ARISTADA INITIO™ (aripiprazole lauroxil) extended-­release injectable suspension [product monograph]. 2020 (last accessed February 2025); https://www.aristadacaresupport.com/downloadables/ARISTADA-­INITIO-­ARISTADA-­Payer-­Hospital-­Monograph.pdf.
8. Jann MW, et al. Clinical pharmacokinetics of the depot antipsychotics. Clin Pharmacokinet 1985; 10:315–333.
9. Bailey L, et al. Estimating the optimal dose of flupentixol decanoate in the maintenance treatment of schizophrenia: a systematic review of the literature. Psychopharmacology 2019; 236:3081–3092.
10. Simpson GM, et al. Single-­dose pharmacokinetics of fluphenazine after fluphenazine decanoate administration. J Clin Psychopharmacol 1990; 10:417–421.
11. Balant-­Gorgia AE, et al. Antipsychotic drugs: clinical pharmacokinetics of potential candidates for plasma concentration monitoring. Clin Pharmacokinet 1987; 13:65–90.
12. Gitlin MJ, et al. Persistence of fluphenazine in plasma after decanoate withdrawal. J Clin Psychopharmacol 1988; 8:53–56.
13. Heres S, et al. Pharmacokinetics of olanzapine long-­acting injection: the clinical perspective. Int Clin Psychopharmacol 2014; 29:299–312.
14. Ravenstijn P, et al. Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-­month formulation in patients with schizophrenia: a phase-­1, single-­dose, randomized, open-­label study. J Clin Pharmacol 2016; 56:330–339.
15. Janssen Pharmaceuticals Inc. Highlights of Prescribing Information. INVEGA TRINZA® (paliperidone palmitate) extended-­release injectable suspension for intramuscular use. 2024 (last checked November 2024); https://www.janssenlabels.com/package-­insert/product-­monograph/ prescribing-­information/INVEGA+TRINZA-­pi.pdf.
16. Janssen Pharmaceuticals Ltd. Highlights of Prescribing Information: INVEGA HAFYERA™ (paliperidone palmitate) extended-­release injectable suspension, for gluteal intramuscular use. 2021 (last checked November 2024); https://www.accessdata.fda.gov/drugsatfda_docs/ label/2021/207946s010lbl.pdf.
17. Barnes TR, et al. Long-­term depot antipsychotics. A risk-­benefit assessment. Drug Saf 1994; 10:464–479.
18. Ogden DA, et al. Determination of pipothiazine in human plasma by reversed-­phase high-­performance liquid chromatography. J Pharm Biomed Anal 1989; 7:1273–1280.
19. US Center for Drug Evaluation and Research. Clinical Pharmacology and Biopharmaceutics Review(s). PERSERIS (Risperidone, RBP-­7000, Risperidone ATRIGEL). 2018 (last checked February 2025); https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210655Orig1s000Cl inPharmR.pdf.
20. Shandong Luye Pharmaceutical Co Ltd. Highlights of Prescribing Information. RYKINDO® (risperidone) for extended-­release injectable suspension for intramuscular use. 2023 (last checked November 2024); https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/ 212849s000lbl.pdf.
21. Walling DP, et al. Pharmacokinetics and safety of a novel extended-­release microsphere formulation of risperidone in patients with schizophrenia or schizoaffective disorder. J Clin Pharmacology 2024; doi: 10.1002/jcph.6143.
22. Laboratorios Farmacéuticos Rovi S A Madrid Spain. Highlights of Prescribing Information. RISVAN® (risperidone) for extended-­release injectable suspension for intramuscular use. 2024 (last checked November 2024); https://www.accessdata.fda.gov/drugsatfda_docs/label/ 2024/214835s000lbl.pdf.
23. Laveille C, et al. Development of a population pharmacokinetic model for the novel long-­acting injectable antipsychotic risperidone ISM®. Br J Clin Pharmacol 2024; 90:2256–2270.
24. Teva Neuroscience Inc. Highlights of Prescribing Information. UZEDY (risperidone) extended-­release injectable suspension for subcutaneous use. 2023 (last checked November 2024); https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213586s000lbl.pdf.
25. Viala A, et al. Comparative study of the pharmacokinetics of zuclopenthixol decanoate and fluphenazine decanoate. Psychopharmacology (Berl) 1988; 94:293–297.
26. Soni SD, et al. Plasma levels of fluphenazine decanoate. Effects of site of injection, massage and muscle activity. Br J Psychiatry 1988; 153:382–384.